Wednesday, October 23, 2013 1:43:24 PM
By Carly Helfand Comment | Forward | Twitter | Facebook | LinkedIn
Last quarter, Eli Lilly managed to up its earnings through raising prices and slashing its workforce. This quarter, the Indianapolis pharma giant ($LLY) built on that strategy while adding some higher revenues from diabetes products into the mix. But at least some analysts are skeptical whether Lilly can hang its hat on its diabetes franchise going forward.
Wednesday, Lilly reported third-quarter earnings that fell 9% to $1.11 a share. But that profit topped analyst estimates, and the company can thank a worldwide sales increase of 6% for at least some of that. Diabetes drugs drove the jump, with Humulin sales leaping 22% in the U.S. and Humalog revenues increasing by 6% at home and 8% abroad.
Lilly also managed to reduce costs again for the quarter, shedding 4% of its operating expenses. Crippled by the patent cliff last year as best-seller Zyprexa fell to generic competition, the company has worked to chip away at losses by cutting down on spending. And with new top-seller Cymbalta about to follow suit, Lilly has once again found itself staring down the barrel of a gun. July company-wide salary freezes followed May layoffs totaling 40% of Lilly's sales force. In October, the company announced $5 billion worth of share buybacks to help pull shareholders through the difficulties still to come.
As far as making up for the sales hit from Zyprexa, Lilly is almost in the clear, according to Goldman Sachs analyst Jami Rubin. "Most of the year-over-year impact from the patent cliff will subside this quarter," she wrote in a note seen by Bloomberg. She also noted that large pharma companies aren't getting the credit they deserve for pipeline products. Assuming FDA approval, Lilly has four new diabetes drugs slated to hit the market in 2014 and 2015, Bloomberg reports.
Those could provide a needed boost for Lilly, whose stock has fallen more than 4% within the last year. Still, Rubin, for one, is not convinced Lilly can ride its diabetes franchise into the sunset, especially with rival drugs from fellow heavyweights Merck ($MRK), Pfizer ($PFE) and Johnson & Johnson ($JNJ) in the works. "Lilly has a clinical program heavy in diabetes where differentiation and reimbursement are likely to be challenging," she said.
___________________________________________________________
LLY
Recent LLY News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 09/18/2024 08:19:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 09:19:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 09:17:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 09:15:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 09:11:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/17/2024 09:08:44 PM
- FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis • PR Newswire (US) • 09/13/2024 08:07:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/12/2024 08:16:25 PM
- Lilly expands manufacturing footprint in Ireland with $1.8 billion investment • PR Newswire (US) • 09/12/2024 09:30:00 AM
- With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes • PR Newswire (US) • 09/10/2024 03:57:00 PM
- Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes • PR Newswire (US) • 09/10/2024 03:18:00 PM
- Apple Loses EU Dispute; Google’s $2.7 Billion Fine Upheld; Oracle Shares Surge 9% • IH Market News • 09/10/2024 10:02:31 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 11:03:46 AM
- Lilly appoints Lucas Montarce as executive vice president and chief financial officer • PR Newswire (US) • 09/09/2024 10:45:00 AM
- In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin • PR Newswire (US) • 09/05/2024 10:45:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:05:08 PM
- Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries • PR Newswire (US) • 09/04/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/28/2024 08:05:08 PM
- High Volatility Expected in Nvidia Report, Ambarella Soars 20%, Hertz Strengthens Board, Apple Cuts Jobs • IH Market News • 08/28/2024 09:50:36 AM
- Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity • PR Newswire (US) • 08/27/2024 10:45:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/26/2024 08:47:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 08:21:53 PM
- IBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without Astronauts • IH Market News • 08/26/2024 12:58:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/23/2024 08:05:09 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2024 04:54:50 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM